First Affiliated Hospital of Harbin Medical University
Who can join
18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
ADP-induced Inhibition of Platelet AggregationPrimary· up to 5 days
The venous blood samples for platelet function test were drawn after an overnight fast, at 12 hours post-last study-drug dose for subjects receiving twice-daily administrations, and at 24 hours post-last study-drug dose for subjects treated with once-daily regimens. The blood was collected in an evacuated vacuum tube containing 3.2% trisodium citrate and lithium heparin. Then the samples were processed within two hours of blood draw according to standard operating procedure. The physical properties of samples were analyzed using Thromboelastography (TEG) Hemostasis Analyzer (CFMS LEPU-8800, Le
Group
Value
95% CI
Clopidogrel 75mg Qdpo.
54.9
31.9 – 79.1
Ticagrelor 90mg Bidpo.
80.6
64.1 – 94
Ticagrelor 45mg Bidpo.
73.6
52.6 – 93.7
Ticagrelor 90mg Qdpo.
66
46.9 – 87
Number of Participants With Bleeding (Major or Minor Bleeding)Primary· up to 5 days
Major bleeding was defined as type ≥ 3 and minor bleeding as types 1 and 2, in accordance to the Bleeding Academic Research Consortium classification. (Mehran R et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.)
Group
Value
95% CI
Clopidogrel 75mg Qdpo.
15
Ticagrelor 90mg Bidpo.
30
Ticagrelor 45mg Bidpo.
14
Ticagrelor 90mg Qdpo.
9
Clopidogrel 75mg Qdpo.
0
Ticagrelor 90mg Bidpo.
0
Ticagrelor 45mg Bidpo.
0
Ticagrelor 90mg Qdpo.
0
Clopidogrel 75mg Qdpo.
1496
Ticagrelor 90mg Bidpo.
471
Ticagrelor 45mg Bidpo.
511
Ticagrelor 90mg Qdpo.
497
ADP-induced Platelet-fibrin Clot Strength (MA)Secondary· up to 5 days
The physical properties of samples were analyzed using Thromboelastography (TEG) Hemostasis Analyzer (CFMS LEPU-8800, Lepu Medical Technology Co., Ltd, Beijing, China) and automated analytical software. TEG test used four channels to detect the effects of anti-platelet therapy via the arachidonic acid (AA) and ADP pathways. TEG test results were expressed in terms of ADP-induced platelet-fibrin clot strength (MA). A MA\>47mm was shown to have a high predictive value for 3-year post-PCI ischemic events during dual antiplatelet therapy. Moreover, ROC curve and quartile analysis suggested MA\<31
Group
Value
95% CI
Clopidogrel 75mg Qdpo.
40.3
27 – 51.6
Ticagrelor 90mg Bidpo.
28.4
18.5 – 38.9
Ticagrelor 45mg Bidpo.
32.3
19.5 – 43.9
Ticagrelor 90mg Qdpo.
34.05
23.6 – 46.1
Number of Participants With High On-Treatment Platelet Reactivity (HTPR)Secondary· up to 5 days
HTPR was defined as IPA ≤ 30% and MA ≥ 47 mm.
Group
Value
95% CI
Clopidogrel 75mg Qdpo.
317
Ticagrelor 90mg Bidpo.
13
Ticagrelor 45mg Bidpo.
23
Ticagrelor 90mg Qdpo.
32
Clopidogrel 75mg Qdpo.
1194
Ticagrelor 90mg Bidpo.
488
Ticagrelor 45mg Bidpo.
502
Ticagrelor 90mg Qdpo.
474
Number of Participants With Cardiovascular Event (Cardiovascular Death, New-onset Myocardial Infarction, or Stroke)Secondary· up to 5 days
Cardiovascular death was defined as sudden cardiac death, fatal myocardial infarction, death due to heart failure, or death due to other cardiovascular causes. Stroke was defined as the focal loss of neurologic function caused by an ischemic or a hemorrhagic event with residual symptoms lasting at least 24 hours or eventually leading to death.
Group
Value
95% CI
Clopidogrel 75mg Qdpo.
0
Ticagrelor 90mg Bidpo.
0
Ticagrelor 45mg Bidpo.
0
Ticagrelor 90mg Qdpo.
0
Clopidogrel 75mg Qdpo.
1511
Ticagrelor 90mg Bidpo.
501
Ticagrelor 45mg Bidpo.
525
Ticagrelor 90mg Qdpo.
506
Clopidogrel 75mg Qdpo.
0
Ticagrelor 90mg Bidpo.
0
Ticagrelor 45mg Bidpo.
0
Ticagrelor 90mg Qdpo.
0
Clopidogrel 75mg Qdpo.
0
Ticagrelor 90mg Bidpo.
0
Ticagrelor 45mg Bidpo.
0
Ticagrelor 90mg Qdpo.
0
Number of Participants With New-onset DyspneaSecondary· up to 5 days
New-onset dyspnea in patients without previous history of dyspnea
Group
Value
95% CI
Clopidogrel 75mg Qdpo.
34
Ticagrelor 90mg Bidpo.
29
Ticagrelor 45mg Bidpo.
32
Ticagrelor 90mg Qdpo.
28
Clopidogrel 75mg Qdpo.
1477
Ticagrelor 90mg Bidpo.
472
Ticagrelor 45mg Bidpo.
493
Ticagrelor 90mg Qdpo.
478
Sponsor's own description
Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients. Recent study found that ticagrelor 90mg twice a day orally could significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular events. The previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in Chinese patients with stable CAD. But large-scale clinical trials are still needed to confirm the effects of low-dose ticagrelor on platelet function in Chinese patients with coronary heart disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06451198 — IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
· Phase 4
· recruiting
NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
· active not recruiting
NCT06584812 — Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects
· Phase 1
· completed
NCT06554821 — A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy
· Phase 1
· completed
NCT06301776 — A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy
· NA
· recruiting
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
NCT07399002 — LONG NAGOMI™ PMCF STUDY
· recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB
· recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease
· Phase 1, PHASE2
· recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO
· NA
· recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under
· NA
· recruiting
Other First Affiliated Hospital of Harbin Medical University trials
Trials by the same sponsor.
NCT07020195 — QFR-Based Functional SYNTAX Score System in Optimizing Revascularization Strategy for Multivessel Disease
· NA
· not yet recruiting
NCT06975592 — Study on the Mechanism of Multi-group Analysis of the Influence of Depression on Common Cardiovascular Diseases
· not yet recruiting
NCT06995456 — Multivariate Analysis and Prediction of Hypertensive Disorder Complicating Pregnancy and Its Related Mechanism
· not yet recruiting
NCT07087093 — Effects of Ketone Esters on Circulating Senescent T Lymphocytes (T Cells) and Inflammation Levels in the Elderly
· NA
· recruiting
NCT06565845 — Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Harbin Medical University
Last refreshed: 30 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03381742.